Simplifying Global Compliance
FDA, EMA Extend Joint Inspection Initiative to Generic Applications
Washington Drug Letter
The FDA and EMA will expand their joint inspection activities to include facilities involved with bioequivalence studies for generic drug applications.
To View This Article:
Buy This Article Now
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing